Table 1.
Research of inhaled siRNA formulations for pulmonary cancer.
| Disease | Target | Administration | Delivery System | Ref. |
|---|---|---|---|---|
| MDR-lung cancer | ABCC3 | Inhalation | LPNs | [17] |
| Lung adenocarcinoma | VEGF | Inhalation | UCNP | [18] |
| Lung cancer | TUBB3 | Oro-tracheal administration |
NPs | [19] |
| Lung cancer | MRP1, BCL2 | Inhalation | NLC | [20] |
| Lung cancer | Akt1 | Inhalation | Nanosized polymer | [21] |
| Lung cancer | Mcl1 | Intratracheal Instillation |
Nanoliposomes | [22] |
| Lung metastasis | STAT3 | Inhalation | PFC | [23] |
| NSCLC | EGFR-TKs | Inhalation | NLC | [15] |
| NSCLC | MRP1, BCL2 | Inhalation | MSN | [24] |
Notes: MDR, multidrug-resistant; LPNs, lipopolymeric nanoparticles; UCNP, up-conversion nanoparticle-based nanocage system; NPs, nanoparticles; NLC, Nanostructured Lipid Carriers; PFC, perfluorocarbon; MSN, mesoporous silica nanoparticles.